Selvigaltin (GB1211), an orally accessible small molecule galectin-3 inhibitor made to be a cure for liver fibrosis and cirrhosis, was evaluated to assess the outcome of hepatic impairment on its pharmacokinetics and security to address regulatory necessities. Inhibition of galectin-three with GB1211 was not connected with any procedure- or dose-connected https://aaronm666xhs8.blog-eye.com/profile